Spotlight on Umoja Biopharma’s Engineered induced Pluripotent Stem Cells (iPSCs) Platform 
April 8, 2022

A Brief History of the CAR T Cell Field While chimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of blood-forming tissue cancers (i.e., hematologic malignancies), major limitations hinder their widespread application. Decades of CAR T cell therapy…


Out of the Lab, Into the Factory: Providing Cancer Immunotherapy to the Masses
December 8, 2021

At Umoja, we know that a cancer immunotherapy is only as good as the patients it reaches. We can do the best, most innovative, most exciting science at the bench, but if the manufacturing process is not scalable, the effort…


Looking Back, Looking Ahead: A Letter from Umoja’s CEO
October 6, 2021

Looking back over the past year, it is gratifying as CEO to reflect on the extraordinary progress we’ve made at Umoja Biopharma.   This year has had no shortage of major accomplishments for the company. Topping the list is our…